The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer (MIBC).

AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. | Imfinzi is ...

Leveraging the power of AI and machine learning technologies, researchers at Weill Cornell Medicine developed a more ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer ...

After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for bladder cancer, making it ... natural killer (NK) and T-cell cells in the body to attack tumours ...

Doctors usually work out the outlook for a certain disease by looking at large groups of people. Primary liver cancer is less common. So survival is harder to estimate than for other, more common ...

Metastatic Urothelial Carcinoma Global Market Report 2025 The Business Research Company's Metastatic Urothelial Carcinoma Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-... ...

According to the American Cancer Society, those with stage 4 non-small cell lung cancer (NSCLC) diagnosed between 2012 and 2018 had a five-year relative survival rate of 9%. However, that doesn't tell ...

Frequent urination and urgency can occur due to other conditions (e.g., a urinary tract or bladder ... such as recent bladder surgery, post-radiology fibrosis, bladder stones, and bladder cancer, ...

Combine an intelligent interviewer with a roster of guests that, according to the Chicago Tribune, would be prized by any talk-show host, and you're bound to get an interesting conversation. Fresh Air ...